One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
Home ➤ Life Science ➤ Pharmaceuticals ➤ Hydroxychloroquine Market
Hydroxychloroquine Market
Hydroxychloroquine Market
Published date: Oct 2023 • Formats:
Request Sample Schedule a Call
  • Home ➤ Life Science ➤ Pharmaceuticals ➤ Hydroxychloroquine Market

Global Hydroxychloroquine Market By Type (Tablet and Active Pharmaceutical Ingredients), By Disease Indication (Malaria, Lupus Erythematosus, COVID-19, Rheumatoid Arthritis, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

  • Published date: Oct 2023
  • Report ID: 101811
  • Number of Pages: 295
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Free Sample
  • Quick Navigation

    • Report Overview
    • Key Takeaways
    • Type Analysis
    • Disease Indication Analysis
    • Distribution Channel Analysis
    • Key Market Segments
    • Drivers
    • Restraints
    • Opportunity
    • Trends
    • Regional Analysis
    • Key Regions
    • Key Players Analysis
    • Recent Development
    • Report Scope

    Report Overview

    Hydroxychloroquine Market size is expected to be worth around USD 11,764 Million by 2032 from USD 1,275 Million in 2022, growing at a CAGR of 20.60% during the forecast period from 2023 to 2032.

    Hydroxychloroquine is in a class of drugs called antimalarial, which is used to prevent and treat malaria in areas where malaria remains sensitive to Chloroquine. Hydroxychloroquine is used as a first-line treatment for diseases such as malaria, rheumatoid arthritis, and other autoimmune disorders. It is an anti-parasite and immunosuppressive drug indicated for the treatment of malaria.

    Recently, hydroxychloroquine has attracted attention owing to its effectiveness in treating patients with COVID-19. Increasing requirements for new hydroxychloroquine and increasing penetration of generic drugs are anticipated to improve the market.

    Hydroxychloroquine Market

    Key Takeaways

    • Market Growth: Hydroxychloroquine market is projected to grow at a CAGR of 20.60% from 2022 to 2032, reaching USD 11,764 million.
    • Primary Use: Hydroxychloroquine is primarily used for malaria treatment, with a 53% market share.
    • COVID-19 Impact: The drug’s demand surged due to its potential in treating COVID-19.
    • Distribution Channels: Hospital pharmacies lead with a dominant market share.
    • Malaria Dominance: The malaria segment holds the maximum market share due to its prevalence in underdeveloped countries.
    • North America’s Share: North America contributes 40% of the global hydroxychloroquine market revenue.
    • Asia-Pacific Growth: The Asia-Pacific region is set to grow rapidly due to government awareness and healthcare investments.

    Type Analysis

    Active Pharmaceutical Ingredients Segment to Witness Significant Growth

    The global hydroxychloroquine market is segmented based on type into tablet and active pharmaceutical ingredients. The active pharmaceutical ingredients segment accounted for the largest market share of 53% during the forecast period due to their responsibility for the beneficial health effects experienced by consumers.

    They are biologically active or directly affect disease treatment, diagnosis, cure, and prevention. However, the tablet segment is recognized for the easy accessibility of the product in tablet form, therefore, is anticipated to develop at a larger CAGR. Additionally, the rise in the high requirement for tablets due to cost-effectiveness and facility of consumption boosted the hydroxychloroquine market growth.

    Disease Indication Analysis

    The Malaria Segment Dominated the Market Growth of the Hydroxychloroquine Market

    Based on disease indication, the global hydroxychloroquine market is divided into malaria, COVID-19, Lupus Erythematosus, Rheumatoid Arthritis, and others. The malaria segment registers the maximum market share. It is anticipated to grow at a steady CAGR during the forecast period due to the rising dominance of malaria in underdeveloped and developing countries.

    Furthermore, there are still countries in African regions considered malaria endemic. Hydroxychloroquine is also listed as an essential medicine by WHO. However, COVID-19 disease indication is anticipated to record the fastest CAGR in the market due to the current disease outbreak caused by the new coronavirus.

    Distribution Channel Analysis

    Hospital Pharmacy Segment Accounted for Dominant Share of the Market

    Based on distribution channels, the global hydroxychloroquine market is classified into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacy section dominated the market share growth and generated the highest revenue share during the forecast period. This is mainly recognized by the growing government advantages to treat malaria in rural areas of underdeveloped and developed countries.

    The retail pharmacy segment is projected to fuel during the forecast period, primarily owing to the substantial development in healthcare infrastructure in emerging countries. Furthermore, the development of the online store’s segment will likely be determined by the rising permeation of attractive discounts, e-commerce, and coupons accessible through online channels.

    Hydroxychloroquine Market

    Key Market Segments

    By Type

    • Tablet
    • Active Pharmaceutical Ingredients

    By Disease Indication

    • Malaria
    • Rheumatoid Arthritis
    • COVID-19
    • Lupus Erythematosus
    • Other Disease Indications

    By Distribution Channel

    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

    Drivers

    The growing Incidence of Malaria in Emerging Asian Countries is Anticipated to Boost the Hydroxychloroquine Market.

    In the previous few years, there has been a rise in the prevalence of malaria in the emerging countries of Asia-Pacific. India is anticipated to have the region’s most significant number of malaria cases. Hydroxychloroquine is amongst the maximum expended drugs opposed to malaria in the country.

    According to the World Malaria Report data, millions of individuals were identified with malaria in India only. According to World Health Organization, worldwide, anticipated millions of individuals suffer from malaria.

    The rise in the Spread of COVID-19 Worldwide is Anticipated to Drive the Market.

    According to the WHO, there are millions of active cases of COVID-19 caused by the new coronavirus and anticipated related deaths of many individuals. Since there is no specific treatment in the market to treat coronavirus and the vaccine against the disease will demand more than 18 months to come to market, healthcare professionals have applied to approve different drugs for disease control and management.

    One such possibility was shown by hydroxychloroquine. Specific studies that were led in various countries used the drug in patients affected with COVID-19. The results displayed the encouraging consequences amongst patients prescribed the drugs. An increase in the prevalence of malaria and rheumatoid arthritis and a rise in the geriatric population are expected to drive market growth.

    Restraints

    Adverse Effects Related to the Use of Hydroxychloroquine Will Hinder Market Growth

    One of the major factors hindering the hydroxychloroquine market growth is the adverse effects related to the drug. Moreover, its clinical efficiency through randomized clinical is not considered for side effects in COVID-19 disease indication. Therefore, the inconsistency of long-term side effects of drug use in treating COVID-19 is anticipated to restrain the market during the forecast period.

    In addition, studies showed that this drug has adverse effects such as stomach aches, diarrhea, and cardiac problems owing to continued use of the drug.

    Opportunity

    Increasing Penetration of Generic Drugs will act as an Opportunity.

    The rise in requirement for novel hydroxychloroquine and increasing generic drug penetration are estimated to influence the market positively. For Example, In March, Novartis AG started delivering millions of hydroxychloroquine tablets to the U.S. Department of Health and Human Services to organize clinical trials to evaluate the effectiveness of hydroxychloroquine in patients with COVID-19 illness.

    The enhanced government support is also projected to significantly influence the market penetration of increasing product approval.

    Trends

    Enhanced Importance by Manufacturers to Develop the Growth Opportunities in the COVID-19 Segment

    The prominent manufacturers of hydroxychloroquine across the globe are utilizing the current outbreak of COVID-19 to increase their production and sale. In addition, studies in U.S. and France showed promising results for drug administration.

    This has advised countries to import a high volume of hydroxychloroquine training to inhibit the spread of the virus. Owing to this rise in drug requirements, manufacturers have raised the production capabilities in their facilities.

    Regional Analysis

    North America Region Accounted Significant Revenue Share of the Global Hydroxychloroquine Market.

    North America accounted for a significant hydroxychloroquine market revenue share of 40%. Owing to the region’s important product for manufacturing and development in healthcare infrastructure. High spending on R&D as well as the accessibility of qualified workers, will further accelerate the market growth rate in this area.

    The Asia-Pacific region is anticipated to grow at a high rate in the forecast period. Due to expanded government awareness campaigns and rising healthcare investments in this area. Additionally, the increasing availability of generic medications will slow the market expansion in this area.

    Hydroxychloroquine Market

    Key Regions

    • North America
      • The US
      • Canada
      • Mexico
    • Western Europe
      • Germany
      • France
      • The UK
      • Spain
      • Italy
      • Portugal
      • Ireland
      • Austria
      • Switzerland
      • Benelux
      • Nordic
      • Rest of Western Europe
    • Eastern Europe
      • Russia
      • Poland
      • The Czech Republic
      • Greece
      • Rest of Eastern Europe
    • APAC
      • China
      • Japan
      • South Korea
      • India
      • Australia & New Zealand
      • Indonesia
      • Malaysia
      • Philippines
      • Singapore
      • Thailand
      • Vietnam
      • Rest of APAC
    • Latin America
      • Brazil
      • Colombia
      • Chile
      • Argentina
      • Costa Rica
      • Rest of Latin America
    • Middle East & Africa
      • Algeria
      • Egypt
      • Israel
      • Kuwait
      • Nigeria
      • Saudi Arabia
      • South Africa
      • Turkey
      • United Arab Emirates
      • Rest of MEA

    Key Players Analysis

    Acquisition of Johnson & Johnson Customers to Provide Leading Position in the Market

    Due to the increasing cases of coronavirus infections across the globe, manufacturers have increased production capabilities in their manufacturing facilities. India is the prominent manufacturer of hydroxychloroquine globally and accounts for the highest market requirement. The prominent key players in the market include such as Zydus Cadila, Sanofi, IPCA Laboratories Ltd, Sandoz International GmbH., and others.

    The following are some of the major players in the global hydroxychloroquine market industry

    Key Market Players

    • Sanofi S.A.
    • Sandoz International GmbH
    • Ipca Laboratories Limited
    • Mylan N.V.
    • Teva Pharmaceutical Industries Limited
    • Bayer AG
    • Zydus Lifesciences Limited
    • Hikama Pharmaceuticals plc.
    • Pfizer Inc.
    • Torrent Pharmaceutical Ltd
    • Zydus Pharmaceutical Inc.
    • Amneal Pharmaceuticals LLC
    • Torrent Pharmaceuticals Ltd
    • Taj Pharmaceuticals Ltd.
    • Cadila Healthcare Ltd.
    • Cipla Inc.
    • Accord Healthcare Inc.
    • Other Key Player

    Recent Development

    • June 2021- Catalent, Inc. pronounced that they would obtain RheinCell Therapeutics GmbH, a prominent inventor and manufacturer of GMP-grade human-encouraged pluripotent stem cells. This achievement will help the company’s prevailing stem cell therapy process manufacturing and development abilities.
    • December 2020- Lonza announced that they had extended their partnership with Aurinia Pharmaceuticals to increase a manufacturing capability for the professional production and manufacturing of Voclosporin.
    • July 2020- The USFDA was notified against using hydroxychloroquine and Chloroquine to administer hospitalized COVID-19 patients with coronavirus owing to the threat of heart rhythm problems, lymph system disease, liver problems, and kidney injuries.

    Report Scope

    Report Features Description
    Market Value (2022) USD 1,275 Mn
    Forecast Revenue (2032) USD 11,764 Mn
    CAGR (2023-2032) 26.60%
    Base Year for Estimation 2022
    Historic Period 2016-2022
    Forecast Period 2023-2032
    Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments
    Segments Covered By Type-Tablet and Active Pharmaceutical Ingredients; By Disease Indication-Malaria, Rheumatoid Arthritis, COVID-19, Lupus Erythematosus, and Other Disease Indications; By Distribution Channel-Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
    Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; The Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA
    Competitive Landscape Sanofi S.A., Sandoz International GmbH, Ipca Laboratories Limited, Mylan N.V., Teva Pharmaceutical Industries Limited, Bayer AG, and Other Key Players
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)

    Frequently Asked Questions (FAQ)

    What’s Hydroxychloroquine?

    It is an antimalarial medication that can also be employed to treat autoimmune conditions such as arthritis, rheumatoid, and Lupus. It's available in tablets and operates by inhibiting the immune system, as well as decreasing inflammation.

    What’s what is the Hydroxychloroquine market?

    Hydroxychloroquine market is the world market for the production, distribution, and sales of Hydroxychloroquine as a drug. It encompasses both brands as well as generic versions of the medicine.

    What was the reason for Hydroxychloroquine being featured in the news?

    The drug received significant public attention in the context of the COVID-19 epidemic. A few early studies as well as anecdotal studies suggested it could offer a potential treatment for COVID-19. However, the subsequent studies and clinical studies yielded inconsistent or even negative findings. There was controversy over its use for COVID-19 prompting a rise in the public's awareness and scrutiny.

    Hydroxychloroquine Market
    Hydroxychloroquine Market
    Published date: Oct 2023
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Sanofi S.A.
    • Sandoz International GmbH
    • Ipca Laboratories Limited
    • Mylan N.V.
    • Teva Pharmaceutical Industries Limited
    • Bayer AG Company Profile
    • Zydus Lifesciences Limited
    • Hikama Pharmaceuticals plc.
    • Pfizer Inc Company Profile
    • Torrent Pharmaceutical Ltd
    • Zydus Pharmaceutical Inc.
    • Amneal Pharmaceuticals LLC
    • Torrent Pharmaceuticals Ltd Company Profile
    • Taj Pharmaceuticals Ltd.
    • Cadila Healthcare Ltd.
    • Cipla Inc.
    • Accord Healthcare Inc.
    • Other Key Player
  • settingsSettings

Related Reports

  • Imaging Photometer Market
  • Sexually Transmitted Disease Market
  • Ashwagandha Market
  • Single-Cell Multiomics Маrkеt
  • Directed Energy Weapons Market
  • Enterprise Blockchain Market

Our Clients

  • Our Clients
Inquiry Before Buying

Hydroxychloroquine Market
  • 101811
  • Oct 2023
    • ★★★★★
      ★★★★★
    • (37)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
Secured Payment Options
Secured Payment Options

© 2025 Market.Us. All Rights Reserved.